Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries.
Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,594.
The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted stock units.
The exercise price for each warrant is DKK 2,594. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 912.34.
The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: firstname.lastname@example.org
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: email@example.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.
Company Announcement no. 18
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Kalvebod Brygge 43
1560 Copenhagen V
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
BlueCat acquires network infrastructure monitoring and automation platform Indeni2.6.2023 19:00:00 CEST | Press release
Customers will gain an enhanced ability to maintain network resiliency TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), announced today that it has acquired Indeni. Moelis & Company acted as financial advisors to BlueCat. Financial terms were not disclosed, and the deal is subject to regulatory approval. Indeni’s platform helps network operations (NetOps) teams assure the health of their network appliances such as firewalls, load balancers, and secure web proxies. It analyzes device configurations, metrics, and logs through deep domain expertise, codified as knowledge. And it alerts administrators about existing and potential issues, using a global, crowd-sourced knowledge base to identify and recommend remediation steps using automation. Customers using Check Point, Palo Alto Networks, Fortinet, F5, and m
Aegon completes share buyback2.6.2023 18:00:00 CEST | Press release
The Hague, June 2, 2023 - Aegon has completed its share buyback program, announced on February 9, 2023, aimed at returning EUR 200 million of surplus cash capital to shareholders. Between February 10, 2023 and June 2, 2023, common shares for an amount of EUR 200 million were repurchased. A total of 46,797,567 common shares were repurchased at an average price of EUR 4.2737 per share. Aegon intends to propose at its next Annual General Meeting of shareholders to cancel these repurchased shares. For further details visit our share buyback updates page at aegon.com. About Aegon Aegon is an integrated, diversified, international financial services group. The company offers investment, protection, and retirement solutions, with a strategic focus on three core markets (the United States, the United Kingdom, and the Netherlands), three growth markets (Spain & Portugal, Brazil, and China), and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all it
Vaisala Oyj: SHARE REPURCHASE 2.6.20232.6.2023 17:30:00 CEST | Press release
VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 2.6.2023VAISALA CORPORATION: SHARE REPURCHASE 2.6.2023In the Helsinki Stock ExchangeTrade date 2.6.2023Bourse trade BuyShare VAIASAmount 1 000SharesAverage price/ share 44,0726EURTotal cost 44 072,60EURVaisala Corporation now holds a total of 171 216 sharesincluding the shares repurchased on 2.6.2023On behalf of Vaisala CorporationNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information Paula Liimattatel +358 9 8949 2020, firstname.lastname@example.org Attachment VAIAS 2.6.2023 trades
Enento Group Plc: SHARE REPURCHASE 2.6.20232.6.2023 17:30:00 CEST | Press release
Enento Group PlcANNOUNCEMENT 2.6.2023Enento Group Plc: SHARE REPURCHASE 2.6.2023In the Helsinki Stock ExchangeTrade date2.6.2023Bourse tradeBuyShareENENTOAmount5,000SharesAverage price/ share18.5640EURTotal cost92,820.00EUREnento Group Plc now holds a total of 141 200 sharesincluding the shares repurchased on 2.6.2023On behalf of Enento Group PlcNordea Bank OyjJanne SarvikiviSami HuttunenFor further information:Arto PaukkuInvestor Relations Officertel. +358 50 469 5380www.enento.com Attachment Enento 2.6 trades
Kommuniké från årsstämma i Cortus Energy AB (publ)2.6.2023 16:50:15 CEST | Pressemelding
Idag, den 2juni 2023, hölls årsstämma i Cortus Energy AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt. Beslut om fastställande av räkenskaper och disposition beträffande bolagets resultat Årsstämman beslutade att fastställa den i årsredovisningen intagna resultat- och balansräkningen. Årsstämman beslutade även att disponera över resultatet i enlighet med förslaget i den framlagda årsredovisningen. Ansvarsfrihet åt styrelseledamöter och verkställande direktör Årsstämman beslutade att bevilja styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2022. Val och arvodering av styrelse och revisor Årsstämman beslutade, i enlighet med valberedningens förslag, om omval av Richard Bagge, Peter Forssell, Rolf Ljunggren, Per-Olov Norberg och Tobias Wennberg, samt om nyval av Lars-Olof Svensson som ordinarie styrelseledamöter. Per-Olov Norberg omvaldes som styrelseordförande. Lars-Olof Svensson, f.1955, är en erfar